ImmunoGen, Inc. Announces Clinical Data Presentations at the 54th ASH Annual Meeting and Exposition
"With ten TAP compounds now in clinical testing — and more in
development behind these — we expect an increasing amount of clinical
data to be reported on TAP compounds for the foreseeable future,"
commented
IMGN901 Oral Presentation
- Title: "Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) In Combination with Lenalidomide (Len) and Dexamethasone (Dex) In Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)" (Abstract #728).
-
When/where:
Dec. 10 at4:45 pm ET in theThomas Murphy Ballroom 2-3 (Session #653).
BT-062 Poster Presentation
- Title: "BT062, An Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity" (Abstract #4042).
-
When/where:
Dec. 10 from6:00-8:00 pm ET in Hall B1-B2 (Session #653; Poster III).
About IMGN901
IMGN901 is wholly owned by ImmunoGen and consists of the Company's CD56-targeting lorvotuzumab antibody with its DM1 cancer-cell killing agent attached using one of its engineered linkers.
IMGN901 is in Phase II testing, in the NORTH trial, for the first-line
treatment of extensive disease small-cell lung cancer (SCLC).
Encouraging findings also have been seen in initial evaluations of the
compound for the treatment of multiple myeloma and Merkel cell carcinoma
(MCC). IMGN901 has been granted orphan drug designation for SCLC,
multiple myeloma and MCC in the US and
About
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including risks related to preclinical and clinical studies, their
timings and results. A review of these risks can be found in ImmunoGen's
Annual Report on Form 10-K for the fiscal year ended
For Investors:
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Source:
News Provided by Acquire Media